Nuvation Bio (NYSE:NUVB – Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Nuvation Bio and Pathfinder Cell Therapy, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvation Bio | 1 | 2 | 8 | 0 | 2.64 |
| Pathfinder Cell Therapy | 0 | 0 | 0 | 0 | 0.00 |
Nuvation Bio currently has a consensus target price of $13.00, indicating a potential upside of 103.73%. Given Nuvation Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Nuvation Bio is more favorable than Pathfinder Cell Therapy.
Insider & Institutional Ownership
Profitability
This table compares Nuvation Bio and Pathfinder Cell Therapy’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvation Bio | -88.18% | -46.59% | -22.01% |
| Pathfinder Cell Therapy | N/A | N/A | N/A |
Valuation and Earnings
This table compares Nuvation Bio and Pathfinder Cell Therapy”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvation Bio | $62.90 million | 35.32 | -$204.63 million | ($0.44) | -14.50 |
| Pathfinder Cell Therapy | N/A | N/A | N/A | N/A | N/A |
Pathfinder Cell Therapy has lower revenue, but higher earnings than Nuvation Bio.
Summary
Nuvation Bio beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
About Pathfinder Cell Therapy
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
